These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30210453)

  • 1. The Androgen Receptor in Breast Cancer.
    Giovannelli P; Di Donato M; Galasso G; Di Zazzo E; Bilancio A; Migliaccio A
    Front Endocrinol (Lausanne); 2018; 9():492. PubMed ID: 30210453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.
    Salvi S; Bonafè M; Bravaccini S
    Semin Cancer Biol; 2020 Feb; 60():132-137. PubMed ID: 31002873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.
    Basile D; Cinausero M; Iacono D; Pelizzari G; Bonotto M; Vitale MG; Gerratana L; Puglisi F
    Cancer Treat Rev; 2017 Dec; 61():15-22. PubMed ID: 29078133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor signaling pathways as a target for breast cancer treatment.
    Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
    Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor function and targeted therapeutics across breast cancer subtypes.
    Kolyvas EA; Caldas C; Kelly K; Ahmad SS
    Breast Cancer Res; 2022 Nov; 24(1):79. PubMed ID: 36376977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer.
    Jinna N; Rida P; Smart M; LaBarge M; Jovanovic-Talisman T; Natarajan R; Seewaldt V
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmenopausal breast cancer, androgens, and aromatase inhibitors.
    Campagnoli C; Pasanisi P; Castellano I; Abbà C; Brucato T; Berrino F
    Breast Cancer Res Treat; 2013 May; 139(1):1-11. PubMed ID: 23572296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
    Gerratana L; Basile D; Buono G; De Placido S; Giuliano M; Minichillo S; Coinu A; Martorana F; De Santo I; Del Mastro L; De Laurentiis M; Puglisi F; Arpino G
    Cancer Treat Rev; 2018 Jul; 68():102-110. PubMed ID: 29940524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor status is highly conserved during tumor progression of breast cancer.
    Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C
    BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Divergent Function of Androgen Receptor in Breast Cancer; Analysis of Steroid Mediators and Tumor Intracrinology.
    Bleach R; McIlroy M
    Front Endocrinol (Lausanne); 2018; 9():594. PubMed ID: 30416486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor.
    Casaburi I; Cesario MG; Donà A; Rizza P; Aquila S; Avena P; Lanzino M; Pellegrino M; Vivacqua A; Tucci P; Morelli C; Andò S; Sisci D
    Oncotarget; 2016 Mar; 7(11):12651-61. PubMed ID: 26862856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Receptor Expression in Breast Carcinoma of Egyptian Patients.
    Samaka RM; Younes SF
    J Clin Diagn Res; 2016 Nov; 10(11):EC17-EC21. PubMed ID: 28050375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor in breast cancer: The "5W" questions.
    Ravaioli S; Maltoni R; Pasculli B; Parrella P; Giudetti AM; Vergara D; Tumedei MM; Pirini F; Bravaccini S
    Front Endocrinol (Lausanne); 2022; 13():977331. PubMed ID: 36111296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
    Jongen L; Paridaens R; Floris G; Wildiers H; Neven P
    Breast Cancer Res Treat; 2016 Feb; 155(3):603-7. PubMed ID: 26868122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse role of androgen action in human breast cancer.
    Takagi K; Yamaguchi M; Miyashita M; Sasano H; Suzuki T
    Endocr Oncol; 2022 Jan; 2(1):R102-R111. PubMed ID: 37435447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
    Christenson JL; Butterfield KT; Spoelstra NS; Norris JD; Josan JS; Pollock JA; McDonnell DP; Katzenellenbogen BS; Katzenellenbogen JA; Richer JK
    Horm Cancer; 2017 Apr; 8(2):69-77. PubMed ID: 28194662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling.
    Al-Zahrani KN; Cook DP; Vanderhyden BC; Sabourin LA
    Oncotarget; 2018 Sep; 9(70):33348-33359. PubMed ID: 30279965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.